Sanchez-Martin Marta - Institute for Cancer Genetics, Columbia University;Institute for Cancer Genetics, Columbia University

基本信息

浏览量：52

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 56 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Abstract 3296: IK-595, a best-in-class MEK-RAF molecular glue, drives broad and potent anti-tumor activity across RAS-MAPK pathway-altered cancers as a monotherapy and in combination

Eric Haines, Rachel Catterall, Victor De Jesus, Daniel Hidalgo, Jill Cavanaugh,Marta Sanchez-Martin, Joseph D. Manna, Michael Burke, Bin Li, Sarah R. Wessel, Ao Yang,Sergio Santillana,

Cancer Researchno. 6_Supplement (2024): 3296-3296

引用0浏览0引用

Abstract 1646: IK-930, a paralog-selective TEAD inhibitor for treating YAP/TAZ-TEAD dependent cancers

Nathan Young, George A. Punkosdy, Jill Cavanaugh, Collin M. Bantle, Alex Constan, Bin Li,James Conley,Marta Sánchez-Martín, Li Xu,Karen McGovern,Alfredo Castro,Michelle Zhang,

Cancer Researchno. 7_Supplement (2023): 1646-1646

引用0浏览0引用

IK-930, a paralog-selective novel TEAD-inhibitor, effectively attenuates drug-tolerant persister cell proliferation

Daniel Hidalgo,Marta Sanchez-Martin,Mihir Rajurkar, George Punkosdy,Jeffrey Ecsedy,Lan Xu

CANCER RESEARCHno. 7 (2023)

引用0浏览0引用

IK-930, a paralog-selective TEAD inhibitor for treating YAP/TAZ-TEAD dependent cancers

Nathan Young, George Punkosdy, Jill Cavanaugh, Collin Bantle, Alex Constan,Bin Li,James Conley,Marta Sanchez-Martin, Lan Xu,Karen McGovern,Alfredo Castro,Michelle Zhang,

CANCER RESEARCHno. 7 (2023)

引用0浏览0引用

Abstract 3852: IK-930, a paralog-selective novel TEAD-inhibitor, effectively attenuates drug-tolerant persister cell proliferation

Daniel Hidalgo,Marta Sánchez-Martín,Mihir Rajurkar, George A. Punkosdy,Jeffrey Ecsedy, Li Xu

Cancer Researchno. 7_Supplement (2023): 3852-3852

引用0浏览0引用

The Aryl Hydrocarbon Receptor Defines a Unique Genomic and Immune Signature in AML Characterized By Monocytic Differentiation, Venetoclax Resistance and Is Targetable By Ahr Antagonist

Jennifer N. Saultz,Daniel Bottomly, Faith Burns,Kaelan Byrd,Yoko Kosaka,Shannon K. McWeeney,Stephen E. Kurtz,Guang Fan,Andy Kaempf,Karen McGovern,Lei Wang,Marta Sanchez-Martin,

Blood（2022）

引用0浏览0引用

IK-930 is a novel TEAD inhibitor for the treatment of cancers harboring mutations in the Hippo signal transduction pathway

Benjamin S. Amidon,Marta Sanchez-Martin,Wilmin Bartolini,Sakeena Syed,Karen McGovern, Lan Xu,Jeffrey Ecsedy,X. Michelle Zhang,Alex Constan,Alfredo C. Castro

CANCER RESEARCHno. 12 (2022)

引用0浏览0引用

Abstract 2156: IK-930 is a novel TEAD inhibitor for the treatment of cancers harboring mutations in the Hippo signal transduction pathway

Benjamin S. Amidon,Marta Sanchez-Martin, Wilmin Bartolini,Sakeena Syed,Karen McGovern, Lan Xu,Jeffrey Ecsedy,X. Michelle Zhang,Alex Constan,Alfredo C. Castro

Cancer Researchno. 12_Supplement (2022): 2156-2156

引用0浏览0引用

A phase 1, first-in-human study of IK-930, an oral TEAD inhibitor targeting the Hippo pathway in subjects with advanced solid tumors

Anthony W. Tolcher,Nehal J. Lakhani,Meredith McKean,Trupti Lingaraj, Laura Victor,Marta Sanchez-Martin,Katherine Kacena,Karim S. Malek,Sergio Santillana

Journal of Clinical Oncologyno. 16_suppl (2022): TPS3168-TPS3168

引用10浏览0引用

IK930, a novel TEAD inhibitor, sensitizes KRAS and EGFR mutant tumors to oncogene targeted therapy

M. Rajurkar,M. Sanchez-Martin, D. Hidalgo, N. Young, B. Amidon, G. Punkosdy, J. Ecsedy, L. Xu

European Journal of Cancer（2022）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn